On Tuesday, 2 research groups presented findings from studies conducted in patients with rheumatoid arthritis (RA) who were switched from reference rituximab to a biosimilar therapy.
At the American College of Rheumatology's 2017 meeting in San Diego, California, 2 research groups presented findings from studies conducted in patients with rheumatoid arthritis (RA) who were switched from reference rituximab to a biosimilar therapy.
The first study,1 by Hans-Peter Tony, MD, and colleagues and presented during an oral poster session, compared the safety and immunogenicity of switching from reference rituximab to GP2013 (Sandoz’s proposed rituximab biosimilar) to continued treatment with reference rituximab in patients with active RA.
The randomized, double-blind, parallel-group study was conducted at 28 centers in the United States and 26 centers in the European Union. Patients (n = 107) had previously received reference rituximab prior to randomization into 2 treatment arms: 1 arm (n = 53) switched treatment to GP2013, and the control arm (n = 54) continued to receive reference rituximab.
The incidence of hypersensitivity was 9.4% in the switch group and 11.1% in the control group. Infusion-related reactions occurred in 11.3% and 18.5% of patients in each group, respectively. Among patients who tested negative for anti-drug antibodies (ADAs) at the time of screening, only 1 patient (in the control group) tested positive for ADAs after the first infusion. The rate of adverse events was similar between the 2 treatment arms.
The researchers concluded that the safety profile of patients who switched from the reference to the biosimilar was comparable with that of the patients who remained on the reference therapy.
The second study,2 presented during a poster session, was conducted by Seung-Cheol Shim, MD, and colleagues. The researchers in this study investigated the safety of CT-P10 (Celltrion and Teva’s proposed rituximab biosimilar) when used long-term after switching from the reference rituximab.
Patients (n = 295) who had completed a previous 48-week main study comparing the pharmacokinetics, safety, and efficacy of CT-P10 and reference rituximab entered into the extension period of this 72-week study. Those who had received CT-P10 or European-sourced reference rituximab during the initial period received CT-P10 in the extension period. Those who had received US-sourced rituximab in the initial period were randomized to receive CT-P10 or US-sourced reference rituximab.
In total, 122 patients continued with CT-P10, 64 continued with US-sourced reference rituximab, 62 switched from US-sourced rituximab to CT-P10, and 47 switched to CT-P10 from European-sourced reference rituximab.
The mean change in the patients’ Disease Activity Score 28 scale (DAS28) from the baseline established by the main study period, as well as the mean change in the American College of Rheumatology response rates, were comparable among all groups. B-cell depletion after the first infusion was also comparable, and was maintained throughout the extention period. The researchers reported no remarkable changes in immunogenicity profiles after switching, and noted that safety profiles were comparable among all groups.
The researchers concluded that long-term effectiveness and tolerability were achieved over 72 weeks of treatment with CT-P10, and that efficacy, pharmacodynamics, safety, and immunogenicity were also comparable among patients who switched their treatments and those who continued with their original therapy.
References
1. Tony HP, Schulze-Koops H, Kruger K, et al. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2795. acrabstracts.org/abstract/comparison-of-switching-from-the-originator-rituximab-to-the-biosimilar-rituximab-gp2013-or-re‑treatment-with-the-originator-rituximab-in-patients-with-active-rheumatoid-arthritis-safety-and/
2. Shim SC, Majstorovic LB, Kasay AB, et al. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2445. acrabstracts.org/abstract/efficacy-and-safety-of-rituximab-biosimilar-ct-p10-after-a-single-switch-from-innovator-rituximabs-in-patients-with-rheumatoid-arthritis-results-from-phase-3-randomized-controlled-trial-over-72-wee/
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024
February 23rd 2024At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).
SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy
January 17th 2024As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.